Teleflex, Arcis enter agreement for cancer diagnostics

Cancer-detection company Arcis Biotechnology said today it has signed an agreement allowing Teleflex (NYSE:TFX) to use Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology.

Daresbury, England-based Arcis’ diagnostics use a two-step nucleic acid extraction and preservation technology. The company said it has an extensive patent portfolio covering DNA and RNA extraction and preservation for downstream processing by qPCR, RT-qPCR and sequencing in under three minutes. The platform may be used for point-of-care, microfluidics or field-based testing, and supports both companies’ drive to improve diagnostic testing and benefit patients and healthcare professionals, Arcis said in a statement.

Get the full story on our sister site, Mass Device.

Intuitive Surgical CEO Guthart to headline DeviceTalks West 2018 Intuitive Surgical enjoyed a nearly two-decade monopoly in the robot-assisted surgery space. At DeviceTalks West, we'll delve into that history as longtime CEO Gary Guthart tells us how he got his start in medtech, how Intuitive came to enjoy such a commanding lead and what the future holds for medical robotics. REGISTER NOW Use code GUTHART to save an additional 10%.